The strongest association was seen with monoclonal antibody CGRP inhibitors, a category that includes medications, including Erenumab and Galcanezumab. The reduced risk was especially noticeable among older adults, women, and people with chronic migraine, suggesting these newer migraine therapies may have additional benefits beyond headache prevention.
